Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

36%

4 trials in Phase 3/4

Results Transparency

25%

2 of 8 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
3(30.0%)
Phase 3
3(30.0%)
Phase 1
2(20.0%)
N/A
1(10.0%)
Phase 4
1(10.0%)
10Total
Phase 2(3)
Phase 3(3)
Phase 1(2)
N/A(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT04471064Phase 1Unknown

A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia

Role: collaborator

NCT01937156Phase 3Completed

A Randomized Controlled Trial of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting

Role: collaborator

NCT05131841Phase 4Unknown

Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC

Role: collaborator

NCT02795260Phase 3Completed

Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65(III-healthy)

Role: collaborator

NCT03794232Not ApplicableCompleted

Effect of Inulin-type Fructose Extracted From Jerusalem Artichoke on Improving Prediabetic State of Type 2 Diabetes

Role: collaborator

NCT02623556Phase 3Completed

Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen

Role: collaborator

NCT02336542Phase 2Completed

Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10

Role: collaborator

NCT02389322Phase 2Completed

Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65

Role: collaborator

NCT02329730Phase 2Completed

Phase IIa Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10

Role: collaborator

NCT01999231Phase 1Completed

Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10

Role: collaborator

NCT01912443Unknown

Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer

Role: collaborator

All 11 trials loaded